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Abstract 
Functional cDNA clones coding for three isoforms of the human prostaglandin E receptor EP, subtype have been isolated from kidney and uterus 
cDNA libraries. The three isoforms, designated hEP,_,, hEP,_,, and hEP,_,,,, have open reading frames corresponding to 390,388 and 365 amino acids, 
respectively. They differ only in the length and amino acid composition of their carboxy-terminal regions, beginning at position 360. The human 
EP, receptor has seven predicted transmembrane spanning domains and therefore belongs to the G-protein-coupled receptor family. The rank order 
of potency for prostaglandins and related analogs in competition for [3H]PGE, specific binding to membranes prepared from transfected COS cells 
was comparable for all three isoforms, and as predicted for the EP, receptor, with PGEz = PGE, >> PGF, = iloprost > PGD, >> U46619. In addition, 
the EP,-selective agonist MB28767 was a potent competing ligand with an IC, value of 0.3 nM, whereas the EP,-selective antagonist AH6909 gave 
IC,, values of 2-7 PM and the EP,-selective agonist butaprost was inactive. In summary, we have cloned three isoforms of the human EP, receptor 
having comparable ligand binding properties. 
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1. Introduction 
The physiological actions of prostaglandin E, (PGE,) 
are mediated through its interaction with specific G-pro- 
tein-coupled EP** receptors [1,2]. There are three sub- 
types of the EP receptor, designated EP,, EP, and EP,, 
which have been identified on the basis of their different 
pharmacological profiles and signal transduction path- 
ways. Thus, activation of the EP,, EP, and EP, subtypes 
results in elevation of intracellular calcium and stimula- 
tion and inhibition of adenylate cyclase, respectively. 
The cloning of the three receptor subtypes has now been 
reported. The sequences of the mouse and human EP, 
receptors [3,4], the mouse and human EP, receptors [5,6] 
and the mouse, rat and bovine EP, receptors [7-l l] are 
all known. In addition, several different isoforms of the 
EP3 subtype have also been identified, EP,,, EP,Band 
*Corresponding author. Fax: (1) (514) 428 8615. 
**Footnote. Prostanoid receptors designated following the recommen- 
dation of the IUPHAR Commission on Receptor Nomenclature and 
Classification [181. 
+ This manuscript is dedicated to the memory of Gretchen Miiller who 
passed away in 1993. 
EP,, in the mouse [8,9] and EP,,, in the cow [l 11. These 
isoforms are produced by alternative splicing and differ 
only in the length and amino acid composition of their 
carboxyl-terminal regions. Most importantly, while the 
EP, receptor isoforms have comparable ligand binding 
affinities, they have been shown to couple to several 
signal transduction pathways within the same cell type, 
including those coupled to both elevation and decrease 
in CAMP [l 11. In this report we describe the cloning, 
expression and ligand binding properties of three differ- 
ent isoforms of the human (h) EP, receptor. 
2. Materials and methods 
2.1. Screening a human kidney cDNA library 
Mouse (m) EP,, receptor [7] cDNA fragments were isolated by 
polymerase chain reaction (PCR) from reverse-transcribed kidney 
poly(A)‘RNA (Clontech, Palo Alto, CA) using the GeneAmp RNA 
PCR kit (Perkin Elmer Cetus, Norwalk, CT). Briefly, 25 pmol of up- 
stream primer A 5’-CCACCATGGCTAGCATGTGGGCGCC-3’ and 
downstream primer B 5’-CTCCAC-GGCCATGGCCGCTGGCCAC- 
C-3’ or upstream primer A’ Y-CCAGCGCCATGGCCGTGGAGC- 
GCGCCC-3’ and downstream primer B’ 5’-GCATCATCTTTCCAG- 
CTGGTCACTCC-3’, synthesized on a Model 380A DNA synthesizer 
(Applied Biosystems, Foster City, CA), were added together with 1 pg 
cDNA, dNTP (200 PM) and Taq polymerase (2.5 unit) in a 100 ~1 
reaction volume (50 mM KCl, 10 mM Tris-HCI (pH 8.3), 2 mM MgCl?, 
for amplification at 95W60 s, 6OW60 s; for 35 cycles in a Perkin 
Elmer Cetus thermal cycler. The 398 bp A/B product (5’ probe) (nucle- 
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otides -5 to 393 [7]) and the 728 bp A/B product (3’ probe) (nucleo- 
tides 374 to 1,101 [7]) were isolated using agarose gel electrophoresis 
followed bv Ma& PCR m&cation (Promega. Madison. WI). 
A human kid&y lgtl 1 cDNA library (Clonjech, Palo Alto, CA) was 
screened with the “P-1abeled mEP,, receptor 5’ and 3’ probes added 
together under standard conditions (50% formamide, 5 x SSPE, 
5 x Denhardt’s olution, 0.1% SDS, lOO,~g/ml sonicated salmon sperm 
DNA) at 42°C overnight. Filters were first washed briefly at room 
temperature with 2 x SSC/O.l% SDS followed by more stringent wash- 
ing (2 x 30 min) at 5O’C with 0.1 x SSC/O.l% SDS. Thirty positive 
phage clones were obtained of which five hybridized strongly with both 
the 5’ and 3’ probes. Phage DNA from the positive clones was prepared 
by the plate lysate method [12]. 
Clone RhkEP,bl was digested with EcoRI and was found to contain 
one insert of 1.8 kb. The 1.8 kb EcoRI fragment (hkEP,&l, designated 
hEP,,) was subcloned into the Bluescript vector KS (Stratagene, La 
Jolla, CA)) and sequenced on both strands using the KS and SK 
primers, or primers generated from the determined sequences. 
2.2. Screening a human uterus cDNA library 
An alternative strategy was also used to screen for the hEP, and 
related prostanoid receptors. An antisense 16-fold degenerate 27mer 
oligonucleotide [13], designated oligo VII(-) [5’-ATA(A,C)ACCCAG- 
GG(A,G)TCCA(A,G)GATCTG(G,A)TT-31, based on the 9 con- 
served amino acids (NQILDPWVY) in transmembrane domain (TMD) 
VII of the TP [14], EP, [3,4] and EP, [7-l l] receptors, was synthesized 
as described above. The “P-1abeled oligo VII(-) probe was used to 
screen a human uterus 1gtlO cDNA library (Clontech, Palo Alto, CA) 
using standard techniques [12]. Briefly, nitrocellulose filters (Schleicher 
and Schuell, Keene, NH) were prehybridized in 6 x SSC, 2 x Den- 
hardt’s solution, 0.2% SDS, 100 pg/ml denatured salmon sperm DNA, 
at 45°C and then hybridized in the same solution containing the “P- 
labeled probe, at 42”C, overnight. Filters were washed briefly at room 
temperature with 6 x SSC followed by washing (2 x 30 min) at 45°C. 
Twenty positive phage clones were obtained and of these 16 hybridized 
with the mouse EP, cDNA probe. Positive phage clones were plaque 
purified and DNA was prepared by the plate lysate method [12]. Clone 
IhuEP,- 21 and ilhuEP,-9, which hybridized with both probes, were 
digested with EcoRI and were found to contain inserts of approxi- 
mately 1.7 kb and 1.4 kb, respectively. The EcoRI fragments (huEP,-21 
and huEP,-9 and designated EPj.,, and EP,,,,) were subcloned into the 
Bluescript vector SK (Stratagene, La Jolla, CA)) and sequenced as 
described above. 
2.3. Construction of the pcDNAIamp-hEP, expression vectors 
The plasmid pKS-hkEP,_, was digested with Hi&III and a 1.7 kb 
hkEP,, cDNA fragment was agarose gel purified. The 1.7 kb Hi&III 
cDNA (hkEP,,) was subsequently subcloned into the Hi&III site of 
pcDNAIamp (Invitrogen, San Diego, CA) and the correct orientation 
was verified by EcoRI digestion. The plasmids pSK-huEP,_,, and pSK- 
huEP,.,,, were digested with EcoRI and the I.7 and 1.4 cDNA fragments 
were gel purified. They were both subsequently subcloned into the 
EcoRI site of pcDNAIamp and the correct orientations were verified 
by PstI digestion. 
2.4. Expression of the human EP, receptor isoforms in COS-M6 cells 
and [‘H]PGE, binding assays 
The three isoforms of the hEP, receptor (hEP,_,, hEP,_,, and hEP3_,,,) 
cDNAs in the pcDNAIamp plasmid (5 pg) were individually trans- 
fected into COS-M6 cells using the DEAE-dextran method with chloro- 
quin [15]. The cells were maintained in culture for 72 h, harvested, 
subjected to lysis by nitrogen cavitation and then membranes were 
prepared by differential centrifugation (1,000 x g for 10 min, then 
100,000 x g for 30 min). [‘H]PGE, binding assays were performed in 10 
mM potassium phosphate (pH 6.0), containing 10 mM MgCl,, 1 mM 
EDTA, 0.5 nM [‘H]PGE, (154 Ci/mmol; Du Pont-New England Nu- 
clear) and 0.5-3 pg of protein from the 100.000 x z membrane fraction. 
Incubations were-conducted for 1 h at room temperature prior to 
separation of the bound and free radioligand by rapid filtration as 
previously described [16]. Residual [‘H]PGE, bound to the filter was 
quantified by liquid scintillation counting. Specific binding was defined 
as the difference between total binding and non-specific binding, deter- 
mined in the presence of 1 ,uM PGE,. 
3. Results and discussion 
We have used PCR generated mEP, [7] cDNA probes 
to clone a hEP, prostanoid receptor from a kidney 
cDNA library. In addition, a degenerate oligonucleotide 
probe, based on the nine conserved amino acids in TMD 
VII of prostanoid receptors [3,4,7-l 1,13,14], was used to 
identify from a uterus cDNA library two additional hEP, 
receptors, which differed only at their carboxy-terminal 
tails (Fig. 1). Hydropathicity analysis (by the Kyte and 
Dolittle method [ 171) predicted the seven putative TMDs 
characteristic of G-protein-coupled receptors. 
The three isoforms of the hEP, receptor, designated 
hP,_,, hEP,,, and hEP3_iII code for proteins containing 
390, 388 and 365 amino acids with calculated molecular 
masses of 43,315, 42,688 and 40,507, respectively. All 
clones contain the same S-untranslated and coding se- 
quences until and including the glutamine residue (amino 
acid 359) located 10 amino acids from the end of TMD 
VII, after which the sequences diverge. This has also 
been found for the the mouse [8,9] and bovine [lo] EP, 
prostanoid receptors. For the mouse, three isoforms 
have been described, EP,,, EP, and EP,, while for the 
bovine four isoforms are known, EP,,,. hEP,, is the 
homologue of the mEP,,, hEP,,, is the homologue of the 
mouse EP,, and bovine EP,, while hEP,,,, is a new 
isoform. The sequences of hEP,,, mEP,,, rat EP, and 
bovine EP,, receptors have been compared in Fig. 2. The 
hEP, cDNAs share approximately 85% amino acid iden- 
tity with the mouse [7-91, rat [lo] and bovine [l l] EP, 
receptors. Differences between the sequences occur 
mainly outside of the seven TMDs. 
The three isoforms of the hEP, receptor subtype were 
analysed by [3H]PGE, binding assays performed with 
membranes prepared from COS cells transfected with 
either hEP,,, hEP,,, or hEP,,,, cDNA. The specific 
binding of [3H]PGE, was of high affinity and saturable 
in each case. The equilibrium dissociation constant (&) 
values were comparable at 0.7 nM , 0.8 nM and 0.9 nM 
for hEP,,, hEP,-,, and hEP,,,,, respectively. High expres- 
sion levels were achieved in all cases with an estimated 
maximum number of specific [3H]PGE, binding sites 
(B,,,) of 14,5 and 20 pmol/mg of membrane protein for 
hEP,,, hEP,,, and hEP3_,iI, respectively. There was no 
[3H]PGE, specific binding detectable in binding assays 
using membranes prepared from non-transfected COS- 
M6 cells or COSM6 cells transfected with the pcD- 
NAlamp vector alone. 
In competition binding assays PGE, and PGE, were 
equipotent in inhibiting [3H]PGE, specific binding to all 
three isoforms with ICsO values of approximately 1 nM 
(Fig. 3 and Table 1). The rank order of atfinities for 
prostaglandins and related analogs was comparable for 
all three isoforms, with PGE, = PGE, >> PGF,, = 
iloprost > PGD, >> U46619. In general, all the compet- 
ing ligands tested displayed the highest affinity for the 
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Fig. 1. Nucleotide and deduced amino acid sequences of the prostanoid EP,., to ,,, receptor cDNAs. The start of each cDNA is indicated and the 
common nucleotide sequence (-195 to 1,077) is shown, followed by specific sequences for each clone. The deduced amino acid sequence (in three 
letter code) is shown below the nucleotide sequence. The positions of the putative transmembrane domains ILVII (based on the hydropathicity profile) 
are indicated by overlines above the nucleotide sequence. Asterisks denote potential N-glycosylation sites and crosses denote potential protein kinase 
C phosphorylation sites. An in-frame stop codon, TAG, in the Y-untranslated region is underlined. 
hEP,_,,, isoform and were 225-fold less active at Table 1). In contrast, the EP,-selective antagonist 
the hEP,_, and hEP,_,, isoforms (Table 1). Several EP- AH6809 was 5-lo-fold less active at the hEP, subtype, 
subtype selective ligands were also evaluated. The EP,- as compared with the hEP, subtype, with IC,, values 
selective agonist MB28767 displayed high affinity for all ranging from 2 to7 ,DM against hEP, as compared with 
three EP, isoforms with I&, values of 0.3 nM (Fig. 3 and 0.5 PM against hEP, [4]. Finally, the EP,-selective ag- 
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Fig. 2. A comparison of EP, receptor amino acid sequences from different species. The deduced amino acid sequences, hown in single letter code, 
of the hEP,_,, bovine (b) EP,,, rat (r) EPg and mEP,, receptors are shown, aligned to optimize homology using a computer program. The boxed 
residues indicate positions where hEP,_, differs from the sequences from the other species. Dots indicate gaps introduced in the sequences for alignment 
purposes. 
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onist butaprost was inactive up to a concentration of 30 
,uM. These radioligand binding data demonstrate that 
the hEP3_i, hEP,_,i and hEP3_iII isoforms all have the li- 
gand binding characteristics predicted for the EP, recep- 
tor subtype. 
In conclusion, we have cloned and expressed three 
isoforms of the human EP3 prostanoid receptor. Fur- 
thermore, we have shown that these isoforms have com- 
parable affinities for prostaglandins, related analogs and 
subtype-selective ligands. The cloning of the human EP3 
receptor isoforms will now allow for the elucidation of 
their signal transduction pathways, distribution and 
their role in biological processes, both in physiological 
and disease states. 
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Fig. 3. Competition for [‘H]PGE2 specific binding to membranes from 
pcDNAIamp-hEP,., transfected COS-M6 cells. [‘HJPGE, binding as- 
says were performed as described in Section 2 in the presence of Panel 
A: 0.03 nM-1OpM PGE, (a). PGE, (o), PGF,, (o), iloprost (o), PGDz 
(A) and U46619 (0) and Panel B: 0.3 nM-100 PM MB28767 (A), 
AH6809 (m) and butaprost (+). Butaprost and AH 6809 were generous 
gifts from Miles Inc and Glaxo Group Research Ltd, respectively. 
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Table 1 
Competition for [3H]PGE, specific binding to membranes from 
pcDNAlamp-hEP,_,, pcDNAlamp-hEP,_,, and pcDNAlamp-hEP,_,,, 
transfected COS-M6 cells 
Competing ligand IC,, (nM) 
Prostaglandins 
PGE, 1.1 1.0 0.9 
PGE, 1.1 1.1 1.1 
PGF,, 271 170 72 
Iloprost 265 171 87 
PGD, 2,621 1,903 555 
U46619 >10,000 >10,000 >10,000 
‘Selective’ Ligands 
MB28767 
AH6809 
Butaprost 
0.3 0.3 0.3 
6,278 4,553 2,025 
>30,000 >30,000 >30,000 
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